NANOPARTICLE-INSULIN AND INSULIN ANALOGUE COMPOSITIONS

The present invention relates to insulin- and insulin analogue-carrying nanoparticles formulated together with or for use with free insulin or with an insulin analogue, such as a rapidly-acting insulin analogue. The compositions of the present invention find use in medicine, particularly in glycemic...

Ausführliche Beschreibung

Gespeichert in:

Bibliographische Detailangaben
Hauptverfasser:	MOUS JAN, RADEMACHER THOMAS
Format:	Patent
Sprache:	eng
Schlagworte:	ACCESSORIES, CLOSURES, OR FITTINGS THEREFOR BABY COMFORTERS CONTAINERS FOR STORAGE OR TRANSPORT OF ARTICLES OR MATERIALS,e.g. BAGS, BARRELS, BOTTLES, BOXES, CANS, CARTONS, CRATES,DRUMS, JARS, TANKS, HOPPERS, FORWARDING CONTAINERS CONTAINERS SPECIALLY ADAPTED FOR MEDICAL OR PHARMACEUTICALPURPOSES CONVEYING DEVICES FOR ADMINISTERING FOOD OR MEDICINES ORALLY DEVICES FOR RECEIVING SPITTLE DEVICES OR METHODS SPECIALLY ADAPTED FOR BRINGINGPHARMACEUTICAL PRODUCTS INTO PARTICULAR PHYSICAL ORADMINISTERING FORMS HANDLING THIN OR FILAMENTARY MATERIAL HUMAN NECESSITIES HYGIENE MEDICAL OR VETERINARY SCIENCE PACKAGES PACKAGING ELEMENTS PACKING PERFORMING OPERATIONS PREPARATIONS FOR MEDICAL, DENTAL, OR TOILET PURPOSES STORING TRANSPORTING
Online-Zugang:	Volltext bestellen
Tags:	Tag hinzufügen Keine Tags, Fügen Sie den ersten Tag hinzu!

Beschreibung
Zusammenfassung:	The present invention relates to insulin- and insulin analogue-carrying nanoparticles formulated together with or for use with free insulin or with an insulin analogue, such as a rapidly-acting insulin analogue. The compositions of the present invention find use in medicine, particularly in glycemic control, e.g. for controlling blood glucose levels in diabetic subjects. Nanoparticle compositions of the invention, formulated together with or for use with free insulin or with an insulin analogue, comprise a nanoparticle comprising a core comprising a metal and/or a semiconductor; and a corona comprising a plurality of ligands covalently linked to the core, wherein said plurality of ligands comprise at least one carbohydrate moiety; and at least one insulin peptide and/or insulin analogue peptide that is non-covalently bound to the corona.